Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms

PHASE3TerminatedINTERVENTIONAL
Enrollment

544

Participants

Timeline

Start Date

September 30, 1999

Primary Completion Date

March 31, 2003

Study Completion Date

March 31, 2003

Conditions
Prostate Cancer
Interventions
DRUG

zoledronic acid

Trial Locations (1)

90095-1781

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY